(filgrastim-aafi)
Filgrastim-aafi is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. NIVESTYM is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. NIVESTYM has a molecular weight of 18‚799 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because NIVESTYM is produced in E coli‚ the product is non-glycosylated and thus differs from G-CSF isolated from a human cell.
NIVESTYM is a sterile‚ clear‚ colorless‚ preservative-free liquid containing filgrastim-aafi injection for subcutaneous or intravenous use. The product is available in single-dose vials for subcutaneous or intravenous use and prefilled syringes for subcutaneous use. The single-dose vials contain either 300 mcg/mL or 480 mcg/1.6 mL of filgrastim-aafi. The single-dose prefilled syringes contain either 300 mcg/0.5 mL or 480 mcg/0.8 mL of filgrastim-aafi. The final pH range of the NIVESTYM drug product solution is 3.8 to 4.3. See Table 4 below for product composition of each single-dose vial or prefilled syringe.
| 300 mcg/mL Vial | 480 mcg/1.6 mL Vial | 300 mcg/0.5 mL Syringe | 480 mcg/0.8 mL Syringe | |
|---|---|---|---|---|
| ||||
Filgrastim-aafi | 300 mcg | 480 mcg | 300 mcg | 480 mcg |
Acetate | 0.59 mg | 0.94 mg | 0.295 mg | 0.472 mg |
Polysorbate 80 | 0.04 mg | 0.064 mg | 0.02 mg | 0.032 mg |
Sodium | 0.035 mg | 0.056 mg | 0.0175 mg | 0.028 mg |
Sorbitol | 50 mg | 80 mg | 25 mg | 40 mg |
Water for Injection USP | 1 mL | 1.6 mL | 0.5 mL | 0.8 mL |
Patient Information | |
What is NIVESTYM? NIVESTYM is a man-made form of granulocyte colony-stimulating factor (G-CSF). G-CSF is a substance produced by the body. It stimulates the growth of neutrophils, a type of white blood cell important in the body's fight against infection. | |
Do not take NIVESTYM if you have had a serious allergic reaction to human G-CSFs such as filgrastim products or pegfilgrastim products. | |
Before you take NIVESTYM, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. | |
How will I receive NIVESTYM?
| |
What are the possible side effects of NIVESTYM? NIVESTYM may cause serious side effects, including:
The most common side effects experienced in patients receiving NIVESTYM include:
These are not all the possible side effects of NIVESTYM. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |
How should I store NIVESTYM?
Keep NIVESTYM out of the reach of children. | |
General information about the safe and effective use of NIVESTYM. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use NIVESTYM for a condition for which it was not prescribed. Do not give NIVESTYM to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about NIVESTYM that is written for healthcare professionals. | |
What are the ingredients in NIVESTYM? Active ingredient: (filgrastim-aafi) Inactive ingredients: acetate, polysorbate 80, sodium, sorbitol, and water for Injection | |
Manufactured by Hospira, Inc., a Pfizer Company, Lake Forest, IL 60045 USA Distributed by Pfizer Labs, division of Pfizer Inc., New York, NY 10001 USA LAB-0935-5.0 | ![]() |
This Patient Information has been approved by the U.S. Food and Drug Administration Revised: March 2023
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.